Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced recent progress across its clinical portfolio, including early ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Sangamo Therapeutics (SGMO) Prices 11M Share Common Offering at $11.50/ShApril 4, 2019 8:03 AM Sangamo Therapeutics (SGMO) Continues to Gain, Now Up 50%April 2, 2019 8:39 AM Sangamo Therapeutics (SGMO) Hits Pre-Market High, Up 26%April 2, 2019 8:09 AM Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy DataApril 2, 2019 7:00 AM